Laporan Laba Rugi (TTM)
Laporan Laba Rugi Spyre Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 15 | 19 | 20 | 7 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Change (%) | 10.21 | 24.14 | 7.27 | -65.03 | -17.43 | -59.88 | -49.98 | 5.41 | -14.17 | -15.94 | -22.35 | -100.00 | NaN | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||
| Cost Of Sales | 54 | 56 | 57 | 62 | 64 | 59 | 59 | 55 | 26 | 14 | 84 | 105 | 152 | 152 |
| Change (%) | 4.48 | 1.83 | 8.98 | 2.88 | -7.67 | -0.85 | -5.47 | -52.64 | -45.66 | 489.75 | 25.17 | 44.12 | 0.00 | |
| % of Revenue | 391.65 | 371.27 | 304.55 | 309.40 | 910.18 | 1,017.73 | 2,515.20 | 4,753.39 | 2,135.83 | 1,352.09 | 9,485.89 | 15,290.26 | ||
| Gross Operating Profit | -40 | -41 | -38 | -42 | -57 | -53 | -56 | -54 | -25 | -13 | -83 | -105 | -152 | -152 |
| Change (%) | 2.51 | -6.39 | 9.81 | 35.32 | -6.46 | 5.59 | -3.62 | -53.88 | -47.21 | 530.14 | 25.67 | 45.07 | -0.00 | |
| % of Revenue | -291.65 | -271.27 | -204.55 | -209.40 | -810.18 | -917.73 | -2,415.20 | -4,653.39 | -2,035.83 | -1,252.09 | -9,385.89 | -15,190.26 | ||
| SG&A | 26 | 27 | 27 | 30 | 31 | 31 | 29 | 25 | 24 | 25 | 34 | 42 | 47 | 49 |
| Change (%) | 4.51 | 1.05 | 9.04 | 2.86 | 0.37 | -7.23 | -12.61 | -4.44 | 6.85 | 35.32 | 22.11 | 11.75 | 4.39 | |
| % of Revenue | 188.87 | 179.10 | 145.79 | 148.20 | 435.89 | 529.82 | 1,225.03 | 2,140.26 | 1,940.39 | 2,415.56 | 3,888.60 | 6,114.97 | ||
| R&D | 2 | 26 | 50 | -26 | -6 | |||||||||
| Change (%) | 95.94 | -78.14 | ||||||||||||
| % of Revenue | 34.99 | 2,093.08 | 4,778.27 | |||||||||||
| OpEx | 80 | 83 | 84 | 92 | 95 | 92 | 87 | 80 | 76 | 90 | 118 | 147 | 173 | 195 |
| Change (%) | 4.49 | 1.58 | 9.00 | 2.88 | -2.92 | -5.18 | -7.81 | -5.67 | 18.90 | 31.56 | 24.28 | 17.42 | 12.81 | |
| % of Revenue | 580.53 | 550.37 | 450.33 | 457.60 | 1,346.07 | 1,582.53 | 3,740.23 | 6,893.65 | 6,169.30 | 8,545.92 | 13,374.49 | 21,405.23 | ||
| Operating Income | -66 | -68 | -66 | -72 | -88 | -86 | -85 | -79 | -75 | -89 | -118 | -147 | -173 | -195 |
| Change (%) | 3.30 | -3.43 | 9.49 | 21.87 | -1.76 | -1.49 | -6.65 | -5.83 | 19.44 | 32.12 | 24.63 | 17.97 | 12.81 | |
| % of Revenue | -480.53 | -450.37 | -350.33 | -357.60 | -1,246.07 | -1,482.53 | -3,640.23 | -6,793.65 | -6,069.30 | -8,445.92 | -13,274.49 | -21,305.23 | ||
| Interest Expense | ||||||||||||||
| Change (%) | ||||||||||||||
| % of Revenue | ||||||||||||||
| Net Income | -66 | -68 | -66 | -72 | -88 | -85 | -84 | -78 | -273 | -294 | -339 | -364 | -186 | -215 |
| Change (%) | 3.46 | -3.33 | 9.45 | 21.51 | -2.37 | -1.90 | -7.18 | 250.33 | 8.03 | 15.07 | 7.51 | -48.94 | 15.55 | |
| % of Revenue | -480.40 | -450.94 | -351.14 | -358.29 | -1,244.84 | -1,471.82 | -3,598.75 | -6,678.20 | -22,195.36 | -27,934.72 | -38,238.15 | -52,939.68 | ||
Source: Capital IQ
